Stereochemistry | RACEMIC |
Molecular Formula | C16H22ClN3O2 |
Molecular Weight | 323.818 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]2CC[N@@]3CCC[C@H]2C3
InChI
InChIKey=GZSKEXSLDPEFPT-LNUXAPHWSA-N
InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10?,14-/m1/s1
Renzapride (BRL-24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist. This compound has a stimulatory effect on gastrointestinal motility and transit. Renzapride has been evaluated for use in treatment of irritable bowel syndrome (IBS). Data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. Phase III clinical trials investigated if this drug could help alleviate the symptoms associated with this type of IBS. However, one phase III study has been terminated due to inefficient efficacy (compared to placebo).
Approval Year
PubMed
ACTIVE MOIETY